Abbvie-Header Abbvie-Header


Find Clinical Drug Development Pipelines & Deals | PipelineProspector


All Data

Filters Filter refresh
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Canakinumab

            Therapeutic Area: Rare Diseases and Disorders Product Name: Ilaris

            Highest Development Status: Approved Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable April 29, 2021


            This new indication follows the existing approval of Ilaris for Systemic Juvenile Idiopathic Arthritis (SJIA)1, now allowing patients over the age of 16 to be treated. Ilaris is an interleukin-1 beta inhibitor that provides a new mode of treatment for this disease.